一品红：全资子公司馥感啉颗粒获药物临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its drug, Fuganlin Granules, aimed at treating adult patients with Qi deficiency cold [1] Group 1 - The full subsidiary of the company, Guangzhou Yipin Hong Pharmaceutical Co., Ltd., is responsible for the drug's development [1] - The clinical trial approval notification number is 2025LP02464, indicating formal recognition by regulatory authorities [1] - The acceptance number for the drug application is CXZL2500048, which is part of the regulatory process [1]